Recent Updates
Recently added Catalysts
CTMX Positive Sentiment

CytomX Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 27, 2023

Wednesday, March 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CytomX Therapeutics, Inc. has announced that it will report its full year 2022 financial results on March 27, 2023. The announcement includes details about a conference call that will follow the results release, allowing participants to access the live event and a recorded replay afterward. This reporting is part of the company's ongoing effort to keep investors informed about its financial performance.
Price reaction · baseline $1.8 (2023-03-21 close) · hit after-hours · 1 other CTMX headline(s) in the window, move may be shared
day 0 close · peak
-3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • CytomX Therapeutics is focusing on its financial performance.
  • The upcoming conference call provides an opportunity for investors to engage with the company.
  • The timely reporting reflects the company's commitment to transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2022 financial results on Monday, March 27, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
SVP, Finance and Accounting
Investor and Media Contact:

Frequently Asked Questions

When will CytomX report its 2022 financial results?

CytomX will report its full year 2022 financial results on March 27, 2023.

What time is the CytomX conference call?

The CytomX conference call is scheduled for 5:00 p.m. ET / 2:00 p.m. PT.

Where can I access the CytomX conference call?

The conference call can be accessed from the Events and Presentations page on CytomX’s website.

Will there be a replay of the conference call?

Yes, an archived replay of the conference call will be available on CytomX's website.

Who should I contact for investor relations?

For investor relations, contact Stephanie Ascher at Stern Investor Relations.

ShareAdd on Google
Tags: CTMX Viatris Investor Conferences Healthcare CytomX financial results Q4 2022 biologics investor relations
Last updated: Mar 22, 2023

Biotech snapshot

Cash runway
$330M liquidity · $6M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CX-2009Phase 2
Neoplasms →

Catalyst track record

+53%
best trade around CTMX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for CTMX.

See every catalyst's timing & PoA →